<DOC>
	<DOCNO>NCT00147745</DOCNO>
	<brief_summary>This study design assess potential mechanism action WelCholÂ® ( colesevelam ) may improve blood glucose control patient type 2 diabetes</brief_summary>
	<brief_title>Effects Colesevelam How Body Responds Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Patients age 18 75 , inclusive Diagnosed type 2 diabetes Hemoglobin A1c value great equal 8.0 % Antidiabetic treatment may include sulfonylurea agent ( nonsulfonylurea agent must withdraw ) Overweight , obese ( body mass index 2545 kg/m2 ) Change dose lipid blood pressure lower therapy within past three month Previous treatment colesevelam hyperlipidemia Serum triglyceride great 500 mg/dL Serum low density lipoproteincholesterol le 60 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Mechanism action insulin sensitivity</keyword>
</DOC>